Eversheds advises BOCI Asia in connection with Consun Pharmaceutical IPO
The Hong Kong office of Eversheds has advised BOCI Asia in connection with the HKD1.09bn (£86m) initial public offering (IPO) of Consun Pharmaceutical Group in Hong Kong.
Consun Pharmaceutical Group — which was successfully listed on 19 December 2013 — is an integrated pharmaceutical company principally engaged in the research, manufacturing and sale of modern Chinese medicines and medical-contrast medium in the PRC. Its key product, uremic clearance granule, is designed for treating kidney disease in the PRC.
The company raised HKD1.09bn by issuing 250 million shares, which represent 25 per cent of the company’s total issued share capital immediately after the completion of the IPO, at HKD4.36 each.
The Hong Kong public offering has been oversubscribed by approximately 130 times.
BOCI Asia, as the sole global co-ordinator, bookrunner, sponsor and lead manager, appointed Eversheds to represent it in this IPO. The Eversheds team was led by partners Stephen Mok and Norman Hui, assisted by Grace Leung, Karen Wang, Man-Wai Wong and Jocelyn Chow.
News from Eversheds
News from The Lawyer
Briefings from Eversheds
The notion of ‘gross negligence’ is an important matter for customers and institutions alike and has been reviewed by the High Court and Supreme Court in deciding a recent case.
This report includes an analysis of the results of Eversheds survey on the Employment Tribunal process, which is based on 180 responses.
Analysis from The Lawyer
Could Slater & Gordon achieve its stated aim of becoming a top consumer brand by acquiring Pannone?
The Mid Staffordshire Inquiry’s call for a duty of candour will have far-reaching effects on the NHS and clinical negligence - if it is ever implemented